Recomendaciones del Grupo Español de Trabajo de Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) para el tratamiento de las fístulas perianales de la enfermedad de Crohn

Boscá, Marta M; Alós, Rafael; Maroto, Nuria; Gisbert, Javier P; Beltrán, Belén; Chaparro, María; Nos, Pilar; Mínguez, Miguel; Hinojosa, Joaquín.
Gastroenterol. hepatol. (Ed. impr.) ; 43(3): 155-168, mar. 2020. ilus, graf, tab
Artículo en Español | IBECS (España) | ID: ibc-190792

Documentos relacionados

  1. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCU.
  2. Allogenic stem cells for Crohn's anal fistulas: Treating early improves the deep remission rate.
  3. [Symptoms, diagnostic and therapy of perianal disease in patients with inflammatory bowel diseases].
  4. Use of Darvadstrocel (Allogenic Stem Cell Therapy) for Crohn's Fistulas in Real Clinical Practice: The National Project to Implement Mesenchymal Stem Cell for the Treatment of Perianal Crohn's Fistula (the PRIME Study).
  5. [Clinical characteristics and prognosis of children with perianal fistulizing Crohn's disease].
  6. Direct health care costs of managing perianal Crohn's Disease in a population based cohort.
  7. Management of perianal fistulas in Crohn's disease: a 2021 update of the French National Society of Coloproctology consensus.
  8. A Phase IB/IIA Study of Ex Vivo Expanded Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease.
  9. Durable Response in Patients With Refractory Fistulizing Perianal Crohn's Disease Using Autologous Mesenchymal Stem Cells on a Dissolvable Matrix: Results from the Phase I Stem Cell on Matrix Plug Trial.
  10. Management of Perianal Crohn's Disease.